HCPCS Level II code A9500 designates a diagnostic dose of technetium tc-99m sestamibi, a radiopharmaceutical widely used in nuclear medicine for myocardial perfusion and select diagnostic imaging studies. This code matters nationally because it standardizes reporting for the radiopharmaceutical agent itself, which affects billing for diagnostic imaging workflows, inventory management, and payer coverage decisions across diverse care settings.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of reimbursement benchmarks and typical site-of-service patterns, a concise clinical context for why technetium tc-99m sestamibi is used, and notes on coding practice and common modifiers. The content summarizes typical utilization scenarios, contrasts outpatient and inpatient administration settings, and highlights areas where policy updates or payer-specific coverage rules commonly influence billing practices.

This summary serves clinicians, billing professionals, and policy analysts seeking a clear, national-level reference for HCPCS Level II code A9500, its clinical use, and the reimbursement landscape affecting diagnostic nuclear medicine services.